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The Recommended Adult Immunization Schedule has been approved by the Advisory
Committee on Immunization Practices, the American College of Obstetricians and
Gynecologists, and the American Academy of Family Physicians. The standard MMWR
footnote format has been modified for publication of this schedule.
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Recommended Adult Immunization
Schedule — United States,
October 2006–September 2007
The Advisory Committee on Immunization Practices
(ACIP) annually reviews the recommended Adult Immuniza-
tion Schedule to ensure that the schedule reflects current rec-
ommendations for the licensed vaccines. In June 2006, ACIP
approved the Adult Immunization Schedule for October
2006–September 2007. This schedule has also been approved
by the American Academy of Family Physicians and the
American College of Obstetricians and Gynecologists.
Changes in the Schedule for
October 2006–September 2007
The 2006–2007 schedule differs from the previous
schedule as follows:
• The broken red line has been deleted on the age-based
schedule (Figure 1). Vaccination of persons with specific
risk factors is now shown only with purple bars.
• Human papillomavirus (HPV) vaccine has been added
to the age-based schedule, with a yellow bar indicating
that the vaccine is recommended for women <26 years.
• Tetanus, diphtheria, and acellular pertussis (Tdap)
vaccine has been added to the age-based schedule, with a
hatched yellow bar indicating that Tdap is a one-time,
1-dose recommendation for persons <64 years.
• The purple bar for varicella vaccine has been shortened
in anticipation of the recommendation for the use of zoster
vaccine in persons aged >60 years.
• A new column has been added to the medical/other indi-
cations schedule (Figure 2) to clarify indications for hepa-
titis A and B vaccines. The indications “chronic liver
disease” and “recipients of clotting factor concentrates”
have been removed from the previous schedule’s third and
fifth columns, respectively, and combined into a new col-
umn. The column has a yellow bar for hepatitis A and B
vaccines, clarifying that these vaccines are recommended
for all persons with these medical indications.
• HPV vaccine has been added to the medical/other indi-
cations schedule, with a yellow bar to indicate the vaccine
is recommended for women aged <26 years with all
indications except pregnancy.
• Tdap was added to the medical/other indications sched-
ule, with a hatched yellow bar to indicate that Tdap is a
one-time, 1-dose recommendation for all indications
except pregnancy.
• The tetanus and diphtheria footnote (#1) has been
reworded to reflect ACIP recommendations for use of Tdap.
• A footnote (#2) has been added to reflect ACIP recommen-
dations for HPV vaccination for all women aged <26 years.
• The measles, mumps, and rubella (MMR) footnote (#3)
has been reworded to reflect ACIP recommendations to
administer a second dose of mumps vaccine to adults in
certain age groups and with certain risk factors.
• The varicella footnote (#4) has been reworded in accor-
dance with ACIP recommendations for administering a
routine second dose for all adults without evidence of
immunity. The footnote also has been revised to reflect
the new definition of immunity to varicella.
• The influenza footnote (#5) has been revised to reflect
recent ACIP recommendations to vaccinate close contacts
of children aged 0–59 months rather than 0–23 months (1).
• The hepatitis B footnote (#9) has been revised to reflect
recommendations to vaccinate any adult seeking protec-
tion from hepatitis B virus infection and vaccinate adults
in specific settings (e.g., sexually transmitted disease clinics) (2).
The Adult Immunization Schedule is available in English
and Spanish at http://www.cdc.gov/nip/recs/adult-
schedule.htm. General information about adult vaccinations,
including recommendations concerning vaccination of per-
son with HIV and other immunosuppressive conditions, is
available from state and local health departments and at http://
www.cdc.gov/nip. Vaccine information statements are avail-
able at http://www.cdc.gov/nip/publications/vis. ACIP state-
ments for each recommended vaccine and provisional vaccine
recommendations can be viewed, downloaded, and printed at
http://www.cdc.gov/nip/publications/acip-list.htm. Instruc-
tions for reporting adverse events to the Vaccine Adverse Event
Reporting System are available at http://www.vaers.hhs.gov
or by telephone, 800-822-7967.
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1. Tetanus, diphtheria, and acellular pertussis (Td/Tdap)
vaccination. Adults with uncertain histories of a complete primary
vaccination series with diphtheria and tetanus toxoid–containing
vaccines should begin or complete a primary vaccination series. A
primary series for adults is 3 doses; administer the first 2 doses at least
4 weeks apart and the third dose 6–12 months after the second.
Administer a booster dose to adults who have completed a primary
series and if the last vaccination was received >10 years previously.
Tdap or tetanus and diphtheria (Td) vaccine may be used; Tdap should
replace a single dose of Td for adults aged <65 years who have not
previously received a dose of Tdap (either in the primary series, as a
booster, or for wound management). Only one of two Tdap products
(Adacel
®
 [sanofi pasteur, Swiftwater, Pennsylvania]) is licensed for use
in adults. If the person is pregnant and received the last Td vaccination
>10 years previously, administer Td during the second or third trimester;
if the person received the last Td vaccination in <10 years, administer
Tdap dur ing the immediate postpartum period. A one-time
administration of 1-dose of Tdap with an interval as short as 2 years
from a previous Td vaccination is recommended for postpartum women,
close contacts of infants aged <12 months, and all health-care workers
with direct patient contact. In certain situations, Td can be deferred
during pregnancy and Tdap substituted in the immediate postpartum
period, or Tdap can be given instead of Td to a pregnant woman after
an informed discussion with the woman (see http://www.cdc.gov/nip/
publications/acip-list.htm). Consult the ACIP statement for
recommendations for administering Td as prophylaxis in wound
management (http://www.cdc.gov/mmwr/preview/mmwrhtml/
00041645.htm).
2. Human papillomavirus (HPV) vaccination. HPV vaccination is
recommended for all women aged <26 years who have not completed
the vaccine series. Ideally, vaccine should be administered before
potential exposure to HPV through sexual activity; however, women
FIGURE 1. Recommended adult immunization schedule, by vaccine and age group — United States, October 2006–September 2007
* Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read along with the footnotes, which can be found on pages Q2–Q4 of this schedule.
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1-dose Td booster every 10 yrs
1–2 doses
2 doses (0, 6–12 mos, or 0, 6–18 mos)
2 doses (0, 4–8 wks) 2 doses (0, 4–8 wks)
1 or 2 doses 1 dose
Influenza *5
1 or more doses
1 dose
1 dose annually1 dose annually
3 doses (0, 1–2, 4–6 mos)
Human papillomavirus
(HPV)2*
Substitute 1 dose of Tdap for Td
3 doses (females)
For all persons in this category who meet the age requirements and who lack evidence
of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Recommended if some other risk factor is (e.g., on the
basis of medical, occupational, lifestyle, or other indications)
present
who are sexually active should still be vaccinated. Sexually active women
who have not been infected with any of the HPV vaccine types receive
the full benefit of the vaccination. Vaccination is less beneficial for women
who have already been infected with one or more of the four HPV
vaccine types. A complete series consists of 3 doses. The second dose
should be administered 2 months after the first dose; the third dose
should be administered 6 months after the first dose. Vaccination is not
recommended during pregnancy. If a woman is found to be pregnant
after initiating the vaccination series, the remainder of the 3-dose
regimen should be delayed until after completion of the pregnancy.
3. Measles, mumps, rubella (MMR) vaccination. Measles component:
adults born before 1957 can be considered immune to measles. Adults
born during or after 1957 should receive >1 dose of MMR unless they
have a medical contraindication, documentation of >1 dose, history of
measles based on health-care provider diagnosis, or laboratory
evidence of immunity. A second dose of MMR is recommended for
adults who 1) have been recently exposed to measles or in an outbreak
setting; 2) have been previously vaccinated with killed measles vaccine;
3) have been vaccinated with an unknown type of measles vaccine
during 1963–1967; 4) are students in postsecondary educational
institutions; 5) work in a health-care facility; or 6) plan to travel
internationally. Withhold MMR or other measles-containing vaccines from
HIV-infected persons with severe immunosuppression. Mumps
component: adults born before 1957 can generally be considered
immune to mumps. Adults born during or after 1957 should receive 1
dose of MMR unless they have a medical contraindication, history of
mumps based on health-care provider diagnosis, or laboratory evidence
of immunity. A second dose of MMR is recommended for adults who 1)
are in an age group that is affected during a mumps outbreak; 2) are
students in postsecondary educational institutions; 3) work in a health-
care facility; or 4) plan to travel internationally. For unvaccinated health-
care workers born before 1957 who do not have other evidence of
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mumps immunity, consider giving 1 dose on a routine basis and strongly
consider giving a second dose during an outbreak. Rubella component:
administer 1 dose of MMR vaccine to women whose rubella vaccination
history is unreliable or who lack laboratory evidence of immunity. For
women of childbearing age, regardless of birth year, routinely determine
rubella immunity and counsel women regarding congenital rubella
syndrome. Do not vaccinate women who are pregnant or who might
become pregnant within 4 weeks of receiving vaccine. Women who do
not have evidence of immunity should receive MMR vaccine upon
completion or termination of pregnancy and before discharge from the
health-care facility.
4. Varicella vaccination. All adults without evidence of immunity to
varicella should receive 2 doses of varicella vaccine. Special consideration
should be given to those who 1) have close contact with persons at high
risk for severe disease (e.g., health-care workers and family contacts of
immunocompromised persons) or 2) are at high risk for exposure or
transmission (e.g., teachers of young children; child care employees;
residents and staff members of institutional settings, including correctional
institutions; college students; military personnel; adolescents and adults
living in households with children; non-pregnant women of childbearing
age; and international travelers). Evidence of immunity to varicella in
adults includes any of the following: 1) documentation of 2 doses of
varicella vaccine at least 4 weeks apart; 2) U.S.-born before 1980
(although for health-care workers and pregnant women, birth before 1980
should not be considered evidence of immunity); 3) history of varicella
based on diagnosis or verification of varicella by a health-care provider
(for a patient reporting a history of or presenting with an atypical case, a
mild case, or both, health-care providers should seek either an
epidemiologic link with a typical varicella case or evidence of laboratory
confirmation, if it was performed at the time of acute disease); 4) history
of herpes zoster based on health-care provider diagnosis; or 5) laboratory
evidence of immunity or laboratory confirmation of disease. Do not
vaccinate women who are pregnant or might become pregnant within 4
weeks of receiving the vaccine. Assess pregnant women for evidence of
varicella immunity. Women who do not have evidence of immunity should
receive dose 1 of varicella vaccine upon completion or termination of
pregnancy and before discharge from the health-care facility. Dose 2
should be administered 4–8 weeks after dose 1.







































































For all persons in this category who meet the age requirements and who lack evidence
of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Recommended if some other risk factor is (e.g., on the
basis of medical, occupational, lifestyle, or other indications)
present
Contraindicated
1-dose Td booster every 10 yrs
1–2 doses
2 doses (0, 6–12 mos, or 0, 6–18 mos)
2 doses (0, 4–8 wks)
1 or 2 doses
1 dose annually1 dose annually
3 doses (0, 1–2, 4–6 mos)
Substitute 1 dose of Tdap for Td







1–2 doses 1–2 doses
3 doses (0, 1–2, 4–6 mos)
1 dose1 dose 1 dose
2 doses (0, 6–12 mos, or 0, 6–18 mos)
* Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read along with the footnotes, which can be found on pages Q2–Q4 of this schedule.
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5. Influenza vaccination. Medical indications: chronic disorders of the
cardiovascular or pulmonary systems, including asthma; chronic
metabolic diseases, including diabetes mellitus, renal dysfunction,
hemoglobinopathies, or immunosuppression (including immuno-
suppression caused by medications or HIV); any condition that
compromises respiratory function or the handling of respiratory
secretions or that can increase the risk of aspiration (e.g., cognitive
dysfunction, spinal cord injury, or seizure disorder or other
neuromuscular disorder); and pregnancy during the influenza season.
No data exist on the risk for severe or complicated influenza disease
among persons with asplenia; however, influenza is a risk factor for
secondary bacterial infections that can cause severe disease among
persons with asplenia. Occupational indications: health-care workers
and employees of long-term–care and assisted living facilities. Other
indications: residents of nursing homes and other long-term–care and
assisted living facilities; persons likely to transmit influenza to persons
at high risk (i.e., in-home household contacts and caregivers of children
aged 0–59 months, or persons of all ages with high-risk conditions);
and anyone who would like to be vaccinated. Healthy, nonpregnant
persons aged 5–49 years without high-risk medical conditions who are
not contacts of severely immunocompromised persons in special care
units can receive either intranasally administered influenza vaccine
(FluMist
®
) or inactivated vaccine. Other persons should receive the
inactivated vaccine.
6. Pneumococcal polysaccharide vaccination. Medical indications:
chronic disorders of the pulmonary system (excluding asthma);
cardiovascular diseases; diabetes mellitus; chronic liver diseases,
including liver disease as a result of alcohol abuse (e.g., cirrhosis);
chronic renal failure or nephrotic syndrome; functional or anatomic
asplenia (e.g., sickle cell disease or splenectomy [if elective splenectomy
is planned, vaccinate at least 2 weeks before surgery]);
immunosuppressive conditions (e.g., congenital immunodeficiency, HIV
infection [vaccinate as close to diagnosis as possible when CD4 cell
counts are highest], leukemia, lymphoma, multiple myeloma, Hodgkin
disease, generalized malignancy, or organ or bone marrow
transplantation); chemotherapy with alkylating agents, antimetabolites,
or high-dose, long-term corticosteroids; and cochlear implants. Other
indications: Alaska Natives and certain American Indian populations
and residents of nursing homes or other long-term–care facilities.
7. Revaccination with pneumococcal polysaccharide vaccine. One-
time revaccination after 5 years for persons with chronic renal failure or
nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell
disease or splenectomy); immunosuppressive conditions (e.g.,
congenital immunodeficiency, HIV infection, leukemia, lymphoma,
multiple myeloma, Hodgkin disease, generalized malignancy, or organ
or bone marrow transplantation); or chemotherapy with alkylating
agents, antimetabolites, or high-dose, long-term corticosteroids. For
persons aged >65 years, one-time revaccination if they were vaccinated
>5 years previously and were aged <65 years at the time of primary
vaccination.
8. Hepatitis A vaccination. Medical indications: persons with chronic
liver disease and persons who receive clotting factor concentrates.
Behavioral indications: men who have sex with men and persons who
use illegal drugs. Occupational indications: persons working with
hepatitis A virus (HAV)–infected primates or with HAV in a research
laboratory setting. Other indications: persons traveling to or working in
countries that have high or intermediate endemicity of hepatitis A (a
list of countries is available at http://www.cdc.gov/travel/diseases.htm)
and any person who would like to obtain immunity. Current vaccines
should be administered in a 2-dose schedule at either 0 and 6–12
months, or 0 and 6–18 months. If the combined hepatitis A and hepatitis
B vaccine is used, administer 3 doses at 0, 1, and 6 months.
9. Hepatitis B vaccination. Medical indications: persons with end-
stage renal disease, including patients receiving hemodialysis; persons
seeking evaluation or treatment for a sexually transmitted disease (STD);
persons with HIV infection; persons with chronic liver disease; and
persons who receive clotting factor concentrates. Occupational
indications: health-care workers and public-safety workers who are
exposed to blood or other potentially infectious body fluids. Behavioral
indications: sexually active persons who are not in a long-term, mutually
monogamous relationship (i.e., persons with >1 sex partner during the
previous 6 months); current or recent injection-drug users; and men
who have sex with men. Other indications: household contacts and sex
partners of persons with chronic hepatitis B virus (HBV) infection; clients
and staff members of institutions for persons with developmental
disabilities; all clients of STD clinics; international travelers to countries
with high or intermediate prevalence of chronic HBV infection (a list of
countries is available at http://www.cdc.gov/travel/diseases.htm); and
any adult seeking protection from HBV infection. Settings where hepatitis
B vaccination is recommended for all adults: STD treatment facilities;
HIV testing and treatment facilities; facilities providing drug-abuse
treatment and prevention services; health-care settings providing
services for injection-drug users or men who have sex with men;
correctional facilities; end-stage renal disease programs and facilities
for chronic hemodialysis patients; and institutions and nonresidential
daycare facilities for persons with developmental disabilities. Special
formulation indications: for adult patients receiving hemodialysis and
other immunocompromised adults, 1 dose of 40 µg/mL (Recombivax HB
®
)
or 2 doses of 20 µg/mL (Engerix-B
®
).
10. Meningococcal vaccination. Medical indications: adults with
anatomic or functional asplenia, or terminal complement component
deficiencies. Other indications: first-year college students living in
dormitories; microbiologists who are routinely exposed to isolates of
Neisseria meningitidis; military recruits; and persons who travel to or
live in countries in which meningococcal disease is hyperendemic or
epidemic (e.g., the “meningitis belt” of sub-Saharan Africa during the
dry season [December–June]), particularly if their contact with local
populations will be prolonged. Vaccination is required by the government
of Saudi Arabia for all travelers to Mecca during the annual Hajj.
Meningococcal conjugate vaccine is preferred for adults with any of
the preceding indications who are aged <55 years, although
meningococcal polysaccharide vaccine (MPSV4) is an acceptable
alternative. Revaccination after 5 years might be indicated for adults
previously vaccinated with MPSV4 who remain at high risk for infection
(e.g., persons residing in areas in which disease is epidemic).
11. Selected conditions for which Haemophilus influenzae type b
(Hib) vaccine may be used. Hib conjugate vaccines are licensed for
children aged 6 weeks–71 months. No efficacy data are available on
which to base a recommendation concerning use of Hib vaccine for
older children and adults with the chronic conditions associated with
an increased risk for Hib disease. However, studies suggest good
immunogenicity in patients who have sickle cell disease, leukemia, or
HIV infection or who have had splenectomies; administering vaccine to
these patients is not contraindicated.
This schedule indicates the recommended age groups and medical indications for routine administration of currently licensed vaccines for persons aged >19 years, as of October 1, 2006.
Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine’s other components are not contraindicated. For detailed
recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers’ package inserts and the complete statements from
the Advisory Committee on Immunization Practices (http://www.cdc.gov/nip/publications/acip-list.htm).
Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available
at http://www.vaers.hhs.gov or by telephone, 800-822-7967.
Information on how to file a Vaccine Injury Compensation Program claim is available at http://www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for
vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.
Additional information about the vaccines in this schedule and contraindications for vaccination is also available at http://www.cdc.gov/nip or from the CDC-INFO Contact Center at 800-
CDC-INFO (800-232-4636) in English and Spanish, 24 hours a day, 7 days a week.
